General Information
Novo Nordisk DM 1 ADJUNCT 4083
The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes. A 26-weeks randomised, insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-centre trial
| Protocol | NN9211-4083 |
|---|---|
| Identifier | NN9211-4083 Site Number 704 V#1157252 |
| UID | 64f5b1a8-0e0f-4c4e-938b-0c14677d9f81 |
| Status | Done - Archived |
| Phase | 3A |
| Category | Diabetes Type 1 |
| Launch Year | 2014 |
| NCT Number | - |
| Created | 2014-04-11 10:34 |
| Last Updated | 2014-04-11 10:34 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2014-09-10 | No |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2014-05-23 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2015-07-17 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Soler, Daniel | DSoler | No |
| Regulatory | - | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Novo Nordisk |
|---|---|
| Division | Novo Nordisk |
| Team | Novo Nordisk |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
